A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer

Inclusion Criteria:

* Age \>= 18 years of age
* Histologically documented breast cancer (hormone receptor (ER/PR) status may be either positive or negative) with or without metastatic disease.
* HER-2(+) as determined by one of the following measurements. NOTE: HER-2(+) assessment may have been on initial diagnosis and need not be repeated for metastatic lesions

  * Immunohistochemistry (IHC) 3+, or
  * FISH + (HER-2 gene signal to centromere 17 signal \>2)
* No transfusion dependent patients and no transfusion within 30 days of leukopheresis
* Documented labs within 7 days of donation consisting of:

  * WBC \> 4.0 K/ul \& \< 11.0 K/ul
  * platelet count \> 150,000/mm3
  * hemoglobin \> 11.0 g/dl.
  * Hematocrit \> 33 %
* Weight \> 110 lbs
* No blood donation in last 8 weeks (blood samples taken for standard of care less then 30 cc/week are acceptable)
* Patients must not have active or unresolved infection.
* No cold or flu sympton at time of donation
* No prior myocardial infarction or active cardiac disease (e.g. congestive heart failure, clinically significant cardiac valvular disease or arrhythmia requiring medications, angina pectoris, uncontrolled hypertension, clinically significant pericardial effusion)
* All patients must give signed written informed consent.
* ECOG Performance Score of 0 or 1.
* Women of childbearing potential must have a negative serum or urine pregnancy test

Exclusion Criteria:

* The presence of another active malignancy
* Pregnant, lactating, or nursing
* Patients with prior myocardial infarction or active cardiac disease (e.g. congestive heart failure, clinically significant cardiac valvular disease or arrhythmia requiring medications, angina pectoris, uncontrolled hypertension, clinically significant pericardial effusion)